8-K ·Filed Jun 30, 2026

ORMP

ORAMED PHARMACEUTICALS INC.
MIXED
Impact 5/10
Horizonweeks Processed3mo ago SEC0001213900-26-073709
8-K context-dependent: Items 8.01
Actionable Insight ◆ Mixed

Monitor Scilex's ability to meet the July 31 and September 30 payment deadlines. Stock settlement alternative introduces dilution risk for Scilex but provides Oramed with a recovery path. The bylaw changes are neutral.

DirectionMixed
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
ORMP ▲ +3.90% at T+60d
NEUTRAL call ✓ call won +3.90% · α vs SPY +1.03% · entry $4.61 → $4.79
Entry anchored
Jun 30, 03:59 PM ET
via exchange tick
T+1d
-0.22%
call -0.22% · α -0.09%
$4.60
settled 3mo ago
T+5d
-6.72%
call -6.72% · α -6.99%
$4.30
settled 3mo ago
T+20d
-13.88%
call -13.88% · α -11.70%
$3.97
settled 2mo ago
T+60d
+3.90%
call +3.90% · α +1.03%
$4.79
settled 9d ago

Price Chart

Loading chart...

Executive Summary

Oramed Pharmaceuticals extended payment obligations from Scilex Holding Company, covering approximately $29.5M Tranche A Note and $6.7M Tranche B Note. Scilex agreed to pay $0.5M immediately and the remaining balance by September 30, 2026, with stock settlement if default occurs. The bylaw amendments are routine governance changes.

Key Facts

  • Extension agreement with Scilex for outstanding notes: Tranche A ~$29.5M, Tranche B ~$6.7M as of June 30, 2026
  • Scilex paid $0.5M on June 25, 2026; further $5M due by July 31, 2026; full balance by September 30, 2026
  • If Scilex defaults, first $1.5M retained as fee and remaining obligations may be settled with Scilex common stock
  • Bylaws amended to simplify record date procedures for stockholder action by written consent and tighten consent delivery timeline

Financial Impact

Total outstanding obligations of approximately $36.2M, representing ~19% of Oramed's market cap. Cash received $0.5M, with $5M due in July and remainder by September.

cash flowscredit risknote receivable

Risk Factors

  • Scilex may fail to make future payments, forcing stock settlement or litigation
  • If stock settlement occurs, Oramed could receive shares of a potentially distressed issuer
  • No guarantee that full principal and interest will be recovered

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (6 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001213900-26-073709
Document: ea0296520-8k_oramed.htm0001213900-26-073709
Document: 0001213900-26-073709-index-headers.html0001213900-26-073709
Document: 0001213900-26-073709-index.html0001213900-26-073709
Document: 0001213900-26-073709.txt0001213900-26-073709
2 reports for ORMP
Performance horizon
Filters
Rows
Reports for ORMP — sortable, filterable
TypeNow
Jul 2, 2026
13w ago
Insider Cluster
NEUTRAL ★ 4/10
$4.60 $4.75▲ +3.26%▼ −0.31%$4.49 (−2.39%)
Jun 30, 2026
13w ago
8-K
MIXED ★ 5/10
$4.61 $4.79▲ +3.90%▲ +1.03%$4.49 (−2.60%)
Showing 2 of 2

US Market Status

Market Closed — Opens Mon (34h 8m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access